MedTrace Logo

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

NCT01208051 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2021-07-15

Study results available
· View outcomes & findings →

Summary

This partially randomized phase I/II trial studies the side effects and best dose of cediranib maleate when given together with or without lenalidomide and to see how well they work in treating patients with thyroid cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of thyroid cancer by blocking blood flow to the tumor. It is not yet known whether cediranib maleate is more effective when given together with lenalidomide in treating thyroid cancer.

Conditions

  • Refractory Differentiated Thyroid Gland Carcinoma
  • Refractory Thyroid Gland Follicular Carcinoma
  • Refractory Thyroid Gland Hurthle Cell Carcinoma
  • Refractory Thyroid Gland Papillary Carcinoma
  • Unresectable Thyroid Gland Carcinoma

Interventions

DRUG

Cediranib

Given PO

DRUG

Cediranib Maleate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Chih-Yi Liao · University of Chicago Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-09
Primary Completion
2020-02-01
Completion
2020-02-01
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208051 on ClinicalTrials.gov